Skin and nail responses after 1 year of infliximab therapy in patients with moderate-to-severe psoriasis: a retrospective analysis of the EXPRESS Trial.
BACKGROUND
The EXPRESS study demonstrated the initial efficacy of infliximab in psoriasis affecting the skin and nails.


OBJECTIVE
To further assess how patients with a positive initial response to infliximab respond to 1 year of continuous infliximab treatment.


METHODS
A retrospective analysis of patients with moderate-to-severe plaque and nail psoriasis who initiated and continued infliximab treatment up to week 46 was conducted.


RESULTS
Among all nail psoriasis patients receiving 1 year of infliximab (n = 186), 74.6 and 54.1% achieved at least 75 or 90% improvement in the Psoriasis Area and Severity Index (PASI) at week 50. These PASI-75 (n = 138) and PASI-90 (n = 100) responders had respective mean improvements from baseline to week 50 of 93.6 and 97.3% for the PASI, 90.6 and 94.1% for the Dermatology Life Quality Index (DLQI) and 78.2 and 80.3% for the Nail Psoriasis Severity Index (NAPSI).


CONCLUSIONS
Infliximab treatment for 1 year produced sustained improvement in PASI, DLQI and NAPSI scores.
Reich
Kristian
K
Dermatologikum Hamburg, Hamburg, Germany. reich@dermatologikum.de
Ortonne
Jean-Paul
JP
Kerkmann
Urs
U
Wang
Yanxin
Y
Saurat
Jean-Hilaire
JH
Papp
Kim
K
Langley
Richard
R
Griffiths
Christopher E M
CE
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009262:Nails / Q000187:drug effects*; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D012189:Retrospective Studies; D012867:Skin / Q000187:drug effects*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab